Unlike classical oncoproteins, ACTL6A exerts context-dependent effects across cancers.8,9 It sustains stemness in hepatocellular carcinoma (HCC), drives metabolic reprogramming in ovarian cancer, and confers therapy resistance in advanced prostate cancer.10-12 Mechanistically, ACTL6A coordinates with transcription factors (e.g., YAP, MYC) to amplify oncogenic signaling while suppressing differentiation and apoptosis.13-15 Despite its emerging significance, critical gaps remain:. The gene discussed is ACTL6A; the disease is Familial prostate cancer.